Systemic ozone therapy and its immunomodulatory effects in COVID-19 patients


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: To evaluate the effect of systemic ozone therapy (OT) on the concentration of pro-inflammatory and anti-inflammatory cytokines in the blood in the complex treatment of COVID-19 patients. Materials and methods: The study included 65 patients with a confirmed diagnosis COVID-19 characterized by a moderate and severe course of the disease. The patients were admitted to the Infectious Disease Hospital of the V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia. The patients’ age ranged from 29 to 78 years. All patients were treated in accordance with the Temporary Guidelines of the Ministry of Health of Russia “Prevention, Diagnosis and Treatment of Coronavirus Infection (COVID-19)”. Two groups of patients were randomly formed. The first group included 35 patients whose complex therapy included OT: intravenous administration of 400 ml of ozonated saline solution with an ozone concentration of 4 mg/L; a total course consisting of 6procedures performed every other day. The second group included 30patients who did not have OT. Clinical and laboratory parameters were evaluated on admission to the Infectious Disease Hospital and after two weeks of complex treatment; clinical, laboratory, special, statistical research methods were used. The content of cytokines GM-CSF, IFN-y, TNF-a, IL-2, IL-4, IL-6, IL-8, IL-10 and their ratios were determined with a multiplex method on the Bioplex 200 analyzer (Bio-Rad, USA) using Bio-Plex Pro Human Cytokine 8-plex Panel (Bio-Rad, USA). Results: On admission to the Infectious Disease Hospital 47/65 (72,3%) patients had a moderate course of the disease and 18/65 (27.7%) patients had a severe one. The length of hospital stay in the group of patients with OT averaged 12.2 (2.7) (8-17) days, and it was 17.9 (4.2) (12-26) days in the group of patients who did not have OT. On admission, all patients had an increase in the level of C-reactive protein in their blood serum; the cytokine content in patients of the groups differed from the initial cytokine level and it was different between groups after two weeks of therapy. The medians of the pro-inflammatory cytokines IL-2, IL-6, IL-8 were particularly different. The content of these cytokines remained elevated in the second group of patients who did not have OT, compared with the baseline data and compared with the first group. The study of anti-inflammatory cytokines showed that the patients of the first group who had OT demonstrated a significantly higher IL-10 content compared to IL-10 content in the patients of the second group. Ratios of pro- and anti-inflammatory cytokines IL-2/IL-10, IL-2/ IL-4, IL-6/IL-10, IL-6/IL-4, IL-8/IL-10, IL-8/IL-4, TNF-a/IL-4 in the first group of patients with OT significantly decreased compared to the baseline indicator, which can be suggestive of a marked decrease in the activity of the inflammatory process. Conclusion: The positive effect of systemic OT on the clinical course of the disease has been revealed. Laboratory indicators in COVID-19 patients have shown a decrease in the severity of the inflammatory response. Besides having anti-inflammatory and immunomodulatory effect, OT helps to stop the process, improve the condition of patients and reduce the length of hospital stay. Systemic OT should be considered as an additional adjuvant method in the complex treatment of patients with SARS-CoV-2 infection.

Full Text

Restricted Access

About the authors

Tatiana A. Fedorova

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: t_fyodorova@oparina4.ru
Dr. Med. Sci., Professor, Head of Transfusional Department

Lyubov V. Krechetova

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: l_krechetova@oparina4.ru
Dr. Med. Sci., Head of the Laboratory of Clinical Immunology

Eteri M. Bakuridze

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: e_bakuridze@oparina4.ru
PhD, Head of the Clinic at the Department of Transfusion and Extracorporeal Hemocorrection

Oleg V. Rogachevsky

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: о_rogachevskiy@oparina4.ru
Dr. Med. Sci., Head of the Department of Extracorporal Methods of Treatment and Detoxification, Professor at the Department of Anesthesiology and Resuscitation

Vladimir Ya. Zaitsev

LLC Firm Medozon

PhD (Chemistry), Director

Elena V. Strelnikova

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: e_strelnikova@oparina4.ru
PhD, doctor at the Department of Extracorporal Methods of Treatment and Detoxification

Aleksey V. Pyregov

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: a_pyregov@oparina4.ru
Dr. Med. Sci., Professor, Director of the Institute of Anesthesiology and Resuscitation

Irena F. Kozachenko

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: i_kozachenko@oparina4.ru
PhD, Leading Researcher at the Gynecological Department

Rosa M. Esayan

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: r_esayan@oparina4.ru
PhD, endocrinologist, Head of the Therapeutic Department

Ksenia G. Khamidulina

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: k_bykova@oparina4.ru
PhD, Researcher at the Department of Extracorporeal Methods of Treatment and Detoxification

Elena V. Inviyaeva

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: e_inviyaeva@oparina4.ru
PhD, Senior Researcher at the Laboratory of Clinical Immunology

Valentina V. Vtorushina

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: v_vtorushina@oparina4.ru
PhD, clinical laboratory diagnostics doctor

Elzyata B. Chudzhaeva

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: chudzhaeva@mail.ru
the nurse at the Therapeutic Department

References

  1. Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID 19. Nat. Rev. Microbiol. 2021; 19(3): 141-54. https://dx.doi.org/10.1038/s41579-020-00459-7
  2. Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020; 368(6490): 473-4. https://dx.doi.org/10.1126/science.abb8925.
  3. Conti P., Ronconi G., Caraffa A., GaUenga C.E., Ross R., Frydas I. et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J. Biol. Regul. Homeost. Agents. 2020; 34(2): 327-31. https://dx.doi.org/10.23812/CONTI-E.
  4. Martinez-Sanchez G., Schwartz A., Donna V.D. Potential cytoprotective activity of ozone therapy in SARS-CoV-2/COVID-19. Antioxidants (Basel). 2020; 9(5): 389. https://dx.doi.org/10.3390/antiox9050389.
  5. PercivaUe E., Clerici M., Cassaniti I., Vecchio Nepita E., Marchese P., Olivati D. et al. SARS-CoV-2 viability on different surfaces after gaseous ozone treatment: a preliminary evaluation. J. Hosp. Infect. 2021; 110: 33-6. https://dx.doi.org/10.1016/j.jhin.2021.01.014.
  6. Yano H., Nakano R., Suzuki Y., Nakano A., Kasahara K., Hosoi H. Inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by gaseous ozone treatment. J. Hosp. Infect. 2020; 106(4): 837-8. https://dx.doi.org/10.1016/j.jhin.2020.10.004.
  7. Cenci A., Macchia I., La Sorsa V., Sbarigia C., Di Donna V., Pietraforte D. Mechanisms of action of ozone therapy in emerging viral diseases: immunomodulatory effects and therapeutic advantages with reference to SARS-CoV-2. Front. Microbiol. 2022; 13: 871645. https://dx.doi.org/10.3389/fmicb.2022.871645.
  8. Chirumbolo S., Valdenassi L., Simonetti V., Bertossi D., Ricevuti G., Franzini M. et al. Insights on the mechanisms of action of ozone in the medical therapy against COVID-19. Int. Immunopharmacol. 2021; 96: 107777. https://dx.doi.org/10.1016/j.intimp.2021.107777.
  9. Министерство здравоохранения Российской Федерации. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (covid-19). Версия 6 (28.04.2020).
  10. Терапевтический профиль. Протокол оценки тяжести состояния пациента (NEWS). Доступно по: https://euat.ru/upload/images/1586077839.pdf?ysclid=l70h8s2eb9327079697
  11. Федорова Т.А., Бакуридзе Э.М., Пырегов А.В., Гаврилова Т.Ю., Козаченко И.Ф., Есаян Р.М., Хамидулина К.Г., Хачатрян Н.А., Иванец Т.Ю., Кречетова Л.В., Инвияева Е.В., Вторушина В.В., Безнощенко О.С., Нечипуренко Д.Ю., Береснева Е.А. Возможности применения системной озонотерапии у пациентов с COVID-19 инфекцией. Биорадикалы и антиоксиданты. 2021; 8(2): 8-24.
  12. Классификация степени тяжести вирусной/CОV-19 пневмонии по КТ. Доступно по: http://www.secondopinions.ru Дата обращения: 27.05.2020.
  13. Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004; 203(2): 631-7. https://dx.doi.org/10.1002/path.1570.
  14. Hernandez A., Papadakos P.J., Torres A., Gonzalez D.A., Vives M., Ferrando C. et al. Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19. Rev. Esp. Anestesiol. Reanim. (Engl. Ed.). 2020; 67(5): 245-52. https://dx.doi.org/10.1016/j.redar.2020.03.004.
  15. The ZOE Health Study. How long does COVID-19 last? UK: London; 2020. Available at: https://covid19.joinzoe.com/post/covid-long-term?fbclid= IwAR1RxIcmmdL-EFjh_aI-. Accessed 15.03.2021.
  16. Wang W., Ye L., Ye L., Li B., Gao B., Zeng Y. et al. Up-regulation of IL-6 and TNF-a induced by SARS-coronavirus spike protein in murine macrophages via NF-xappaB pathway. Virus Res. 2007; 128(1-2): 1-8. https://dx.doi.org/10.1016/j.virusres.2007.02.007.
  17. Olbei M., Hautefort I., Modos D., Treveil A., Poletti M., Gul L. et al. SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients. Front. Immunol. 2021; 12: 629193. https://dx.doi.org/10.3389/fimmu.2021.629193.
  18. Gubernatorova E.O., Gorshkova E.A., Polinova A.I., Drutskaya M.S. IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020; 53: 13-24. https://dx.doi.org/10.1016/j.cytogfr.2020.05.009.
  19. Озон против COVID-19 - Ассоциация Российских Озонотерапевтов. Потенциальное использование озона при инфекции SARS-CoV-2/COVID-19. 2020. Доступно по: www.ozonetherapy.ru
  20. Rowen R., Robins H. A plausible “penny” costing effective treatment for corona virus - ozone therapy. J. Infect. Dis. Epidemiol. 2020; 6(2): 113. https://dx.doi.org/10.23937/2474-3658/1510113.
  21. Franzini M., Valdenassi L., Ricevuti G., Chirumbolo S., Depfenhart M., Bertossi D., Tirelli U. Oxygen-ozone (O2-O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported. Int. Immunopharmacol. 2020; 88: 106879. https://dx.doi.org/10.1016/j.intimp.2020.106879.
  22. Hamilton J.A., Whitty G.A., Stanton H., Meager A. Effects of macrophage-colony stimulating factor on human monocytes: induction of expression of urokinase-type plasminogen activator, but not of secreted prostaglandin E2, interleukin-6, interleukin-1, or tumour necrosis factor-alpha. J. Leukoc. Biol. 1993; 53(6): 707-14. https://dx.doi.org/10.1002/jlb.53.6.707.
  23. Takahashi G.W., Andrews D.F. 3rd, Lilly M.B., Singer J.W., Alderson M.R. Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes. Blood. 1993; 81(2): 357-64.
  24. Martinez-Sanchez G. Mechanisms of action of O3. Genomic pathways. Ozone Ther. Glob. J. 2019; 9(1): 21-2.
  25. Martinez-Sanchez G., Delgado-Roche L. Up-date on the mechanisms of action of ozone through the modification of cellular signaling pathways. Role of Nrf2 and NFkb. Rev. Esp. Ozonoterapia. 2017; 7: 17-8.
  26. Li W., Khor T.O., Xu C., Shen G., Jeong W.S., Yu S. et al. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem. Pharmacol. 2008; 76(11): 1485-9. https://dx.doi.org/10.1016/j.bcp.2008.07.017.
  27. Li Q., Verma I.M. NF-xappaB regulation in the immune system. Nat. Rev. Immunol. 2002; 2(10): 725-34. https://dx.doi.ois/10.1038/nri910.
  28. Araimo F., Imperiale C., Tordiglione P., Ceccarelli G., Borrazzo C., Alessandri F. et al. Ozone as adjuvant support in the treatment of COVID-19: a preliminary report of probiozovid trial. J. Med. Virol. 2021; 93(4): 2210-20. https://dx.doi.org/10.1002/jmv.26636.
  29. Хаммад Е.В., Никитин И.Г., Федорова К.В. Применение озонотерапии у пациентов с новой коронавирусной инфекцией COVID-19. Вестник восстановительной медицины. 2020; 5(99): 94-100. [Hammad E.V., Nikitin I.G., Fedorova K.V. Ozone Therapy in Patients with the New Coronavirus Infection COVID-19. Bulletin of Restorative Medicine. 2020; 5(99): 94-100. (in Russian)]. https://dx.doi.org/10.38025/2078-1962-2020-99-5-94-100.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies